Samantasinghar Anupama, Sunildutt Naina Pullarkat, Ahmed Faheem, Soomro Afaque Manzoor, Salih Abdul Rahim Chethikkattuveli, Parihar Pratibha, Memon Fida Hussain, Kim Kyung Hwan, Kang In Suk, Choi Kyung Hyun
Department of Mechatronics Engineering, Jeju National University, the Republic of Korea.
Department of Electrical Engineering, Sukkur IBA University, Pakistan.
Biomed Pharmacother. 2023 May;161:114408. doi: 10.1016/j.biopha.2023.114408. Epub 2023 Feb 24.
Antibody Drug Conjugate (ADC) is an emerging technology to overcome the limitations of chemotherapy by selectively targeting the cancer cells. ADC binds with an antigen, specifically over expressed on the surface of cancer cells, results decrease in bystander effect and increase in therapeutic index. The potency of an ideal ADC is entirely depending on several physicochemical factors such as site of conjugation, molecular weight, linker length, Steric hinderance, half-life, conjugation method, binding energy and so on. Inspite of the fact that there is more than 100 of ADCs are in clinical trial only 14 ADCs are approved by FDA for clinical use. However, to design an ideal ADC is still challenging and there is much more to be done. Here in this review, we have discussed the key components along with their significant role or contribution towards the efficacy of an ADC. Moreover, we also explained about the recent advancement in the conjugation method. Additionally, we spotlit the mode of action of an ADC, recent challenges, and future perspective regarding ADC. The profound knowledge regarding key components and their properties will help in the synthesis or production of different engineered ADCs. Therefore, contributes to develop an ADC with low safety concern and high therapeutic index. We hope this review will improve the understanding and encourage the practicing of research in anticancer ADCs development.
抗体药物偶联物（ADC）是一种新兴技术，通过选择性靶向癌细胞来克服化疗的局限性。ADC与一种抗原结合，该抗原在癌细胞表面特异性高表达，可减少旁观者效应并提高治疗指数。理想ADC的效力完全取决于几个物理化学因素，如偶联位点、分子量、连接子长度、空间位阻、半衰期、偶联方法、结合能等。尽管有100多种ADC正在进行临床试验，但美国食品药品监督管理局（FDA）仅批准了14种ADC用于临床。然而，设计理想的ADC仍然具有挑战性，还有很多工作要做。在这篇综述中，我们讨论了关键组成部分及其对ADC疗效的重要作用或贡献。此外，我们还解释了偶联方法的最新进展。此外，我们还重点介绍了ADC的作用模式、近期挑战以及ADC的未来前景。有关关键组成部分及其特性的深入知识将有助于不同工程化ADC的合成或生产。因此，有助于开发出安全性低、治疗指数高的ADC。我们希望这篇综述能增进理解并鼓励开展抗癌ADC开发研究。
